EYEN Insider Trading

Insider Ownership Percentage: 7.10%
Insider Buying (Last 12 Months): $1,042,540.00
Insider Selling (Last 12 Months): $0.00

Eyenovia Insider Trading History Chart

This chart shows the insider buying and selling history at Eyenovia by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Eyenovia Share Price & Price History

Current Price: $1.13
Price Change: Price Increase of +0.025 (2.27%)
As of 04/1/2025 03:19 PM ET

This chart shows the closing price history over time for EYEN up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$1.10Closing price on 03/31/25:

SEC Filings (Institutional Ownership Changes) for Eyenovia (NASDAQ:EYEN)

25.84% of Eyenovia stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at EYEN by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$60kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5M$0$5MTotal InflowsTotal Outflows
Eyenovia logo
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Read More on Eyenovia

Today's Range

Now: $1.13
Low: $1.06
High: $1.13

50 Day Range

MA: $2.11
Low: $1.10
High: $4.80

52 Week Range

Now: $1.13
Low: $1.06
High: $124.80

Volume

23,576 shs

Average Volume

150,240 shs

Market Capitalization

$1.57 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Who are the company insiders with the largest holdings of Eyenovia?

Eyenovia's top insider shareholders include:
  1. Stuart M Grant (Major Shareholder)
  2. Tsontcho Ianchulev (Director)
  3. Michael M Rowe (CEO)
  4. Charles E Iv Mather (Director)
  5. Ellen R Strahlman (Director)
  6. John P Gandolfo (CFO)
  7. Bren Kern (COO)
Learn More about top insider investors at Eyenovia.